CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, announced that its UCLA res...
AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC por...
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is appro...
Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOB...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National...
Zai Lab Limited announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYRO™ ...
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of bett...
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-i...
Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer Mariana Oncology ...
Biomerica Inc. , a global leader in innovative medical diagnostics, proudly announces a landmark multi-year exclusive distribution agreement with one of th...
Hyundai Bioscience announced its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cance...
Gain Therapeutics, a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapi...
Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...
LUMISIGHT™ and Lumicell™ Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may h...
© 2025 Biopharma Boardroom. All Rights Reserved.
